Evidence map›Paper›PMID 29590132›Full record

ArticlePloS one2018

GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis.

Chengshi Wang, Ling Li, Shuyun Liu, Guangneng Liao, Lan Li, Younan Chen, Jingqiu Cheng, Yanrong Lu, Jingping Liu

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 101 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. New Insights into the Role of Mitochondrial Dysfunction in Diabetic Kidney Disease in the Omics Era.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Chengshi WangKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Ling LiDivision of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Shuyun LiuKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Guangneng LiaoKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Lan LiKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Younan ChenKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Jingqiu ChengKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Yanrong LuKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.
Jingping LiuKey Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0001-8364-639X
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence indicates that obesity is highly associated with chronic kidney disease (CKD). GLP-1 receptor (GLP-1R) agonist has shown benefits on kidney diseases, but its direct role on kidney metabolism in obesity is still not clear. This study aims to investigate the protection and metabolic modulation role of liraglutide (Lira) on kidney of obesity. Rats were induced obese by high-fat diet (HFD), and renal function and metabolism changes were evaluated by metabolomic, biological and histological methods. HFD rats exhibited systemic metabolic disorders such as obesity, hyperlipidemia and impaired glucose tolerance, as well as renal histological and function damages, while Lira significantly ameliorated these adverse effects in HFD rats. Metabolomic data showed that Lira directly reduced renal lipids including fatty acid residues, cholesterol, phospholipids and triglycerides, and improved mitochondria metabolites such as succinate, citrate, taurine, fumarate and nicotinamide adenine dinucleotide (NAD+) in the kidney of HFD rats. Furthermore, we revealed that Lira inhibited renal lipid accumulation by coordinating lipogenic and lipolytic signals, and partly rescued renal mitochondria function via Sirt1/AMPK/PGC1α pathways in HFD rats. This study suggested that Lira alleviated HFD-induced kidney injury at least partly via directly restoring renal metabolism, thus GLP-1R agonist is a promising therapy for obesity-associated CKD.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAMP-Activated Protein KinasesAnimalsFibrosisHomeostasisKidneyLipid MetabolismLiraglutideMaleMetabolomicsMitochondriaObesityPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRatsRats, Sprague-DawleySignal TransductionAMP-Activated Protein KinasesGlucagon-Like Peptide-1 Receptor AgonistsLiraglutidePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaSirt1 protein, ratSirtuin 1

Identifiers

PMID29590132
PMCPMC5873987
OpenAlexW2795005430

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.